AbbVie Inc (ABBV)vsLive Ventures Inc (LIVE)
ABBV
AbbVie Inc
$201.55
-0.57%
HEALTHCARE · Cap: $358.55B
LIVE
Live Ventures Inc
$13.25
+0.61%
CONSUMER CYCLICAL · Cap: $40.70M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 14113% more annual revenue ($62.82B vs $441.98M). ABBV leads profitability with a 5.8% profit margin vs 5.0%. LIVE trades at a lower P/E of 2.8x. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
LIVE
Hold44
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-19.7%
Fair Value
$168.33
Current Price
$201.55
$33.22 premium
Margin of Safety
+89.0%
Fair Value
$177.00
Current Price
$13.25
$163.75 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 31.6%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Every $100 of equity generates 26 in profit
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 45.8%
Distress zone — elevated risk
Smaller company, higher risk/reward
5.0% margin — thin
Operating margin of 3.2%
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.57 suggests the stock is reasonably priced for its growth.
Bull Case : LIVE
The strongest argument for LIVE centers on P/E Ratio, Price/Book, Return on Equity.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 98.9x leaves little room for execution misses.
Bear Case : LIVE
The primary concerns for LIVE are Market Cap, Profit Margin, Operating Margin.
Key Dynamics to Monitor
LIVE carries more volatility with a beta of 1.06 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 44/100) and 12.4% revenue growth. LIVE offers better value entry with a 89.0% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Live Ventures Inc
CONSUMER CYCLICAL · HOME IMPROVEMENT RETAIL · USA
Live Ventures Incorporated is engaged in flooring manufacturing, steel fabrication and retail businesses in the United States. The company is headquartered in Las Vegas, Nevada.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?